Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 6Terminated 3Withdrawn 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Recurrence 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia 1Hematologic Neoplasms 1

Interventions

Rituximab 16Cyclophosphamide 12fludarabine phosphate 8Peripheral Blood Stem Cell Transplantation 7Vincristine 5Radiotherapy 5Prednisone 5Lenalidomide 5Etoposide 5Doxorubicin 5Cytarabine 5Bendamustine Hydrochloride 5fludarabine 4Whole-Body Irradiation 4Filgrastim 4tazemetostat 3Mycophenolic Acid 3Melphalan 3Carmustine 3umbralisib 2ublituximab 2sargramostim 2parsaclisib 2ofatumumab 2ibritumomab tiuxetan 2duvelisib 2Tacrolimus 2Pentostatin 2Pentetic Acid 2Methotrexate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma, Follicular × ofatumumab × Clear all
NCT01263418 2015-10-12

Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas

UNC Lineberger Comprehensive Cancer Center

Phase 2 Withdrawn
Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT00092274 2015-04-21

Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma

GlaxoSmithKline

Phase 1/2 Withdrawn
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡